An £88 million EPR programme just hit pause.

Norfolk and Waveney University Hospitals Group has delayed the go-live of its Meditech Expanse EPR by a year. Not because the programme failed. But because leadership decided that going live before they were truly ready would not serve patients, clinicians, or the wider community.

That decision deserves more attention than it will probably get.

Too often, EPR success is framed around dates. Milestones. The “Big Bang.” We talk about excitement and fireworks, as if switching on a system is the finish line. In reality, it is the point of greatest risk.

When an EPR goes live, it does not just change screens. It changes how clinicians think, how information flows, how decisions are made, and how care is delivered under pressure. If that system is not fully understood, fully exercised, and fully trusted, patients feel it first.

We already know the consequences. Some trusts have reported losses of up to 20 percent in clinical activity during EPR go-lives. That is not an abstract metric. That is delayed care, longer waits, and additional strain on frontline teams. No amount of digital ambition makes that acceptable.

What stands out in Norfolk’s approach is the acknowledgement that this is not simply an IT deployment. It is a translation exercise. Meditech Expanse may be proven elsewhere, but it is new to the English NHS. It must be adapted to local workflows, local reporting needs, and local realities across three acute trusts. Rushing that translation risks breaking what already works.

This is where many programmes stumble.

Validation is often treated as something you get through so you can go live. In practice, validation is how you prove that the system supports safe care before patients are exposed to it. Not partial testing. Not optimistic assumptions. But end to end, clinically informed validation that confirms results are accurate, workflows behave as expected, and staff can rely on the system in the moments that matter most.

The most important line in this story is not about dates or contracts. It is about ownership. A system that is locally owned, causes no disruption, and delivers the benefits it promises over the long term.

That is a very different definition of success.

As the NHS accelerates its digital ambitions, we should be clear about what success really looks like. Digital transformation is not measured by how fast systems are switched on, but by how safely they are embedded into care. When programmes prioritise thorough validation, clinical confidence, and local readiness, patients and communities are the ones who benefit most.

Sometimes the bravest digital decision is to slow down.

And sometimes, delaying go-live is exactly how you protect patients.

Source: Digital Health News, January 2026.